Info
🌱來自: alki in nsclc
KFSYSCC Fellowship Tuesday Morning Journal Club
2023-12-12
Treatment of
ALK Translocation-Positive
Non-Small Cell Lung Cancer
Siblings
- KFSYSCC Fellowship Tuesday Morning Journal Club
- [[林協霆,1; 吳茂青2]]
- Patient 1: 58-year-old man
- Increasing number of FDA-approved drugs for treatment of oncogene-addicted NSCLC
- Anaplastic lymphoma kinase and ALK inhibitors
- Domain structure of receptor tyrosine kinase families
- Gene fusion between EML4 and ALK
- Signaling Pathways Activated by ALK Fusion Proteins
- Therapeutic Sequencing in ALK+ NSCLC
- [[1st generation ALKi]]
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
- [[2nd generation of ALKi]]
- Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
- [[Alectinib vs crizotinib in ALK+ NSCLC (J-ALEX):
an open-label, randomised phase 3 trial]] - Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA)
- OS
- Alectinib versus chemotherapy in crizotinib pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer
- Outcome
- [[2nd generation ALKi]]
- Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
- Survival without intracranial disease progression with brain metastasis at baseline
- Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib
- Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
- [[Yet another 2nd generation ALKi]]
- [[First-line ceritinib versus platinum-based chemotherapy]]
- [[3rd generation ALKi]]
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- Cumulative Incidence of CNS Progression as First Event
- Timeline in the development of the AEs of lorlatiib
- Compare Trials of ALKi
- Schematic total PFS comparison
- Mechanisms of resistance of ALKi
- Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
- PFS by EML4-ALK v1 versus v3 detected by cDNA (CROWN, ALEX, ALTAl-1L)
- Secondary Mutations within EML4-ALK
- Characteristics of the pooled population of 450 ALK inhibitor resistant
- Clinical Benefit for ALK Resistance Mutations From Sequential ALK Inhibitors
- Take Home Message
- [[Have a nice day]]
- Addendum
- ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer